Affibody AB Revenue and Competitors
Estimated Revenue & Valuation
- Affibody AB's estimated annual revenue is currently $22.2M per year.
- Affibody AB's estimated revenue per employee is $155,000
Employee Data
- Affibody AB has 143 Employees.
- Affibody AB grew their employee count by 7% last year.
Affibody AB's People
| Name | Title | Email/Phone |
|---|---|---|
1 | Head Global Programs | Reveal Email/Phone |
2 | Solutions Architect | Reveal Email/Phone |
Affibody AB Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $123.5M | 797 | 8% | N/A | N/A |
#2 | $22.2M | 143 | 7% | N/A | N/A |
#3 | $32.1M | 207 | 2% | N/A | N/A |
#4 | $10.1M | 65 | -16% | N/A | N/A |
#5 | $4.3M | 28 | -35% | N/A | N/A |
#6 | $21.4M | 138 | 20% | N/A | N/A |
#7 | $22.6M | 146 | -15% | N/A | N/A |
#8 | $11.2M | 72 | 6% | N/A | N/A |
#9 | $8.1M | 52 | -26% | N/A | N/A |
#10 | $4M | 26 | 13% | N/A | N/A |
What Is Affibody AB?
Affibody is a clinical stage Swedish biotech company focused on developing next generation biopharmaceuticals based on its unique proprietary technology platforms: Affibody® molecules and Albumod. Affibody is developing a portfolio of innovative drug projects and, in addition, offers the half-life extension technology, Albumod, for outlicensing. The company is currently developing four proprietary programs. The first three are therapeutic programs that targets liver diseases, autoimmune diseases, and psoriasis respectively. The fourth program is a diagnostic imaging program that is directed primarily towards metastatic breast cancer. Affibody also has ongoing commercial relationships with several companies such as AbClon, Biotest, Daewoong, Daiichi Sankyo, GE Healthcare, Nordic Nanovector, and Swedish Orphan Biovitrum. Affibody was founded in 1998 by researchers from the Royal Institute of Technology and the Karolinska Institute and is based in Stockholm, Sweden.
keywords:N/A
N/A
Total Funding
143
Number of Employees
$22.2M
Revenue (est)
7%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Affibody AB News
Competitive Spectrum Top Companies Participating in the High Mobility Group Protein B1 Market are: Affibody AB Cantex Pharmaceuticals Inc
The major players [Affibody AB, Cantex Pharmaceuticals Inc, Dicerna Pharmaceuticals Inc, Evec Inc, Ribomic Inc] who are leading the High ...
Interleukin 17A MarketReport 2019 provides a regional analysis of the global Interleukin 17A Market to display key/Companies opportunities ...
Global High Mobility Group Protein B1 Market 2019-2026 | Top key players are Affibody AB ,Cantex Pharmaceuticals Inc ,Dicerna ...
Other Companies in Solna
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $55.9M | 144 | -28% | N/A |
#2 | $34.2M | 148 | 56% | N/A |
#3 | $29.5M | 158 | 4% | N/A |
#4 | $15M | 166 | 7% | N/A |
#5 | $59.3M | 166 | 5% | N/A |